A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice

Two recently approved PARP inhibitors provide an important new therapeutic option for patients with BRCA-mutated metastatic breast cancer. PARP inhibitors significantly prolong progression-free survival in patients, but conventional oral delivery of PARP inhibitors is hindered by limited bioavailabi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Theranostics
Autori principali: Zhang, Di, Baldwin, Paige, Leal, Ana S., Carapellucci, Sarah, Sridhar, Srinivas, Liby, Karen T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ivyspring International Publisher 2019
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735511/
https://ncbi.nlm.nih.gov/pubmed/31534547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.36281
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi